Literature DB >> 7757079

A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria.

J Lamoril1, P Martasek, J C Deybach, V Da Silva, B Grandchamp, Y Nordmann.   

Abstract

Hereditary coproporphyria (HC) is an acute hepatic porphyria with autosomal dominant inheritance caused by a deficient activity of coproporphyrinogen IX oxidase (CPX). We previously described harderoporphyria, a homozygous variant form of coproporphyria in three siblings, characterized by a massive excretion of harderoporphyrin and a marked decrease of coproporphyrinogen IX oxidase activity. In this kindred, the transmission of the disease was autosomal recessive. In the present study, sequencing of cDNA and genomic DNA from these patients revealed a point mutation resulting in a lysine to glutamic acid substitution (K304E) in exon 6 of the gene and the absence of the normal allele, suggesting a homozygous state for the mutation. Expression studies of normal and mutated cDNAs in E. coli demonstrated that this amino acid substitution was responsible for the important decrease in the enzyme activity and for the accumulation of harderoporphyrin. The Michaelis constant of the mutated enzyme was 10-fold higher than normal suggesting that the lysine at position 304 is important for binding the substrate: a slightly increased sensitivity to thermal denaturation was also observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757079     DOI: 10.1093/hmg/4.2.275

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria.

Authors:  J Lamoril; H Puy; S D Whatley; C Martin; J R Woolf; V Da Silva; J C Deybach; G H Elder
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

2.  Cystathionine-γ-lyase (CSE) deficiency increases erythropoiesis and promotes mitochondrial electron transport via the upregulation of coproporphyrinogen III oxidase and consequent stimulation of heme biosynthesis.

Authors:  Katalin Módis; V-M Sadagopa Ramanujam; Armita Abdollahi Govar; Ernesto Lopez; Karl E Anderson; Rui Wang; Csaba Szabo
Journal:  Biochem Pharmacol       Date:  2019-08-14       Impact factor: 5.858

3.  Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria.

Authors:  U B Rüfenacht; L Gouya; X Schneider-Yin; H Puy; B W Schäfer; R Aquaron; Y Nordmann; E I Minder; J C Deybach
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

4.  Neonatal-Onset Hereditary Coproporphyria: A New Variant of Hereditary Coproporphyria.

Authors:  Kosei Hasegawa; Hiroyuki Tanaka; Miho Yamashita; Yousuke Higuchi; Takayuki Miyai; Junko Yoshimoto; Ayumi Okada; Norihiro Suzuki; Keiji Iwatsuki; Hirokazu Tsukahara
Journal:  JIMD Rep       Date:  2017-03-28

5.  Role of aspartate 400, arginine 262, and arginine 401 in the catalytic mechanism of human coproporphyrinogen oxidase.

Authors:  Jason R Stephenson; Julie A Stacey; Justin B Morgenthaler; Jon A Friesen; Timothy D Lash; Marjorie A Jones
Journal:  Protein Sci       Date:  2007-01-22       Impact factor: 6.725

6.  Structural basis of hereditary coproporphyria.

Authors:  Dong-Sun Lee; Eva Flachsová; Michaela Bodnárová; Borries Demeler; Pavel Martásek; C S Raman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-21       Impact factor: 11.205

Review 7.  Hepatic porphyrias in children.

Authors:  G H Elder
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

8.  Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R.

Authors:  Alev Hasanoglu; Manisha Balwani; Ciğdem S Kasapkara; Fatih S Ezgü; Ilyas Okur; Leyla Tümer; Alpay Cakmak; Irina Nazarenko; Chunli Yu; Sonia Clavero; David F Bishop; Robert J Desnick
Journal:  J Inherit Metab Dis       Date:  2010-11-20       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.